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Abstract
Background: Fibrosis of the intestine is a common and poorly understood complication of Crohn’s disease (CD)
characterized by excessive deposition of extracellular matrix and accompanied by narrowing and obstruction of the
gut lumen. Defining the molecular characteristics of this fibrotic disorder is a vital step in the development of
specific prediction, prevention, and treatment strategies. Previous epigenetic studies indicate that alterations in DNA
methylation could explain the mechanism by which mesenchymal cells adopt the requisite pro-fibrotic phenotype
that promotes fibrosis progression. However, to date, genome-wide analysis of the DNA methylome of any type of
human fibrosis is lacking. We employed an unbiased approach using deep sequencing to define the DNA
methylome and transcriptome of purified fibrotic human intestinal fibroblasts (HIF) from the colons of patients with
fibrostenotic CD.
Results: When compared with normal fibroblasts, we found that the majority of differential DNA methylation was
within introns and intergenic regions and not associated with CpG islands. Only a low percentage occurred in the
promoters and exons of genes. Integration of the DNA methylome and transcriptome identified regions in three
genes that inversely correlated with gene expression: wingless-type mouse mammary tumor virus integration site
family, member 2B (WNT2B) and two eicosanoid synthesis pathway enzymes (prostacyclin synthase and
prostaglandin D2 synthase). These findings were independently validated by RT-PCR and bisulfite sequencing.
Network analysis of the data also identified candidate molecular interactions relevant to fibrosis pathology.
Conclusions: Our definition of a genome-wide fibrosis-specific DNA methylome provides new gene networks and
epigenetic states by which to understand mechanisms of pathological gene expression that lead to fibrosis. Our
data also provide a basis for development of new fibrosis-specific therapies, as genes dysregulated in fibrotic
Crohn’s disease, following functional validation, can serve as new therapeutic targets.
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Background
Intestinal fibrosis is a devastating complication of
Crohn’s disease (CD), a major type of inflammatory
bowel disease (IBD) [1]. Characterized by a chronic
transmural inflammation of the intestine, CD is disab-
ling, incurable, and of unknown etiology. The associated
fibrosis comprises prolonged abnormal wound repair
and tissue remodeling leading to excessive deposition of
a collagen-containing extracellular matrix (ECM).
Hypertrophy of the submucosa and muscularis is a
major contributor to the increased rigidity and thickness
of the bowel wall. These changes typically lead to stric-
ture formation and fibro-stenosis, a major cause of ser-
ious complications and surgical procedures in CD
patients. In the absence of fibrosis-specific drugs, anti-
inflammatory therapies have not prevented or reduced
the incidence of fibrosis. For the CD patients that suc-
cumb to this complication, surgical intestinal resection
is currently the only treatment option and provides tem-
porary symptomatic relief without cure or alteration of
disease progression [2]. In this context, the ability to
predict the patients that develop fibrosis remains an im-
portant challenge that would significantly improve the
clinical management of IBD.
A number of factors have been proposed to have a role
in the etiology of CD [1, 3, 4]. These include genetic sus-
ceptibility, defects in innate immunity, undefined envir-
onmental factors, and alterations in the microbiome.
Recent genome-wide association studies appear to ex-
plain only a minority of the risk associated with develop-
ment of CD [5, 6]. The high rate of discordance among
monozygotic twins and the increased prevalence of CD
over recent decades suggest environmental factors may
be at play. As epigenetic changes are dynamically re-
sponsive to the environment, they are likely to play a
key role in the pathogenesis of fibrosis and to offer a
molecular explanation for how the intestine becomes
pro-fibrotic.
DNA methylation is the addition of a methyl group to
the 5-position of the DNA base cytosine. Genome-wide
changes in DNA methylation have been shown to be
major contributors to cancer, mammalian development,
gene transcription, and phenotype in a range of diseases
[7, 8], including a variety of autoimmune and inflamma-
tory conditions. Recent epigenetic profiling of IBD pa-
tients has comprised DNA methylome signatures of colon
tissue, whole blood, and B cells for both major types of in-
flammatory bowel disease: ulcerative colitis (UC) and CD
[9–13]. Of the few previous studies, two of these corre-
lated changes in DNA methylation with gene expression
[12, 13] and only one analyzed a purified (B cells) cell type
[10]. Furthermore, of the three previous studies that have
analyzed epigenetic changes in intestinal fibrogenesis,
none of these defined changes in DNA methylation. One,
from our lab, showed that chromatin modifications are
linked with activation of type I collagen gene expression
in endothelial to mesenchymal transition [14], a feature of
intestinal fibrosis in vivo. The two other labs focused on
specific miRNAs in the fibrotic intestine [15, 16]. More-
over, all published studies to date of the DNA methylation
in fibrotic diseases have been limited to studying restricted
subsets of genes or to the use of microarrays that lack
genome-wide coverage [17–23]. We report here the use of
an unbiased, genome-wide approach to define the DNA
methylome and the transcriptome of fibroblasts isolated
from colons of control and CD patients. This approach
avoids the issues of heterogeneity of tissue/biopsy samples
and employs next generation sequencing using the
methyl-CpG binding domain (MBD) of MBD2, called
MBD-isolated genome sequencing (MiGS). MiGS is based
on the capacity of MBD2 to bind with high affinity and
specificity to DNA containing densely methylated cyto-
sines [24]. A sequencing library heavily enriched for these
methylated sequences within sheared genomic DNA is
coupled to next generation sequencing so that the location
of DNA methylation at specific genomic loci can be quan-
tified and compared. We integrated this information with
RNA sequencing (RNA-seq) data to identify key molecu-
lar interactions that lead to fibrosis pathology. Our identi-
fication of key differentially methylated regions (DMRs) in
intestinal fibrosis provides new molecular characteristics
for fibrostenotic CD and a resource for studying epigen-
etic mechanisms that could help classify different stages of
fibrosis and identify patients predisposed to developing
this major complication of IBD.
Results
Genome-wide changes in DNA methylation in fibrotic
human intestinal fibroblasts
Genome-wide DNA methylation profiles were generated
from human intestinal fibroblasts (HIF) isolated from
colon resection specimens that were either normal or
from patients with fibrostenotic CD. We identified sta-
tistically significant regions of differential DNA methyla-
tion between the two groups at a false discovery rate
(FDR) threshold of <5 %. Both quantitative and qualita-
tive differences in DNA methylation were detected
(Additional file 1). Qualitative differences were defined
as sharp yes/no DNA methylation with a clear presence
or absence of DNA methylation between the normal and
fibrotic groups. In sharp yes/no DMRs, one group has
zero or statistically near-zero sequencing reads, indicat-
ing a lack of methylation, whereas the other group
shows a strong enrichment of reads, indicating the pres-
ence of methylation. Heatmap visualization and hier-
archical clustering of the sharp yes/no DMRs showed a
striking difference between the DMRs in normal and CD
samples (Fig. 1a). These sharp yes/no DMRs were
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detected throughout the genome on all 22 autosomes
(Fig. 1b). Of the sharp yes/no DMRs, 1180 DMRs repre-
sent hypermethylation in the fibrotic samples as com-
pared to the normal samples, and 802 represent
hypomethylation. We focused further analysis on quali-
tative differences in methylation because the quantitative
differences (where both conditions are statistically differ-
ent and have high numbers of reads) are likely methyl-
ated in all conditions [25].
Genomic and CpG island context of differential DNA
methylation in intestinal fibrosis
Evidence from recent studies suggests that the genomic lo-
cation of DNA methylation is a major contributor to the
type of function performed by this epigenetic modification
[7, 8]. Based on the global distribution of the hyper- and
hypo-DNA methylated loci, we determined the fre-
quency of loci in promoter, inter-, and intragenic re-
gions (Fig. 1c and Additional file 1). Promoter regions
were defined as +1000 bp to −500 bp relative to tran-
scription start sites, 3′ end gene regions as +1000 bp
to −1000 bp of transcription termination sites, and
intergenic regions as the remaining regions of the gen-
ome. The NCBI reference sequence database (RefSeq)
was used to define the transcription units for all genes.
In the cases where DMRs were located in multiple
gene regions, the overlaps were prioritized as follows:
promoter > 3′ end > exon > intron > intergenic. Only
a minor percentage of the mapped differential DNA
methylation occurred in promoters (5.0 and 2.7 % for
hypermethylated and hypomethylated DMRs, respect-




































































































Fig. 1 Genome-wide differentially methylated regions (DMRs) in fibrotic human intestinal fibroblasts (HIF). a Heatmap of read counts at all sharp
yes/no DMRs. Square root transformed read counts were plotted for each detected DMR. Higher read counts (red) indicate stronger evidence for
the presence of methylation. Lower and zero read counts (blue) indicate absence of methylation. Each row represents one DMR. Read counts
have been normalized to the number of 50-bp windows in each DMR. b Karyogram showing genome-wide coverage of differentially methylated
regions (DMRs). Hypermethylated (red) and hypomethylated (blue) regions in Crohn’s disease HIF when compared to normal controls are shown.
Black lines above each chromosome represent regions covered by sequencing reads to show genome-wide coverage. c The proportion of DMRs
that overlap with promoters, gene 3′ ends, exons, introns, and intergenic regions is shown. RefSeq genes were used to define transcription units.
d The number of sharp yes/no DNA methylated loci in CpG islands versus CpG shores (2000-bp flanking CpG islands), shelves (2000-bp regions
flanking shores), and open sea regions (loci greater than 4 kb from CpG islands) is shown
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regions (40.8 and 48.4 %). DNA methylation within
gene bodies has also been reported to have an import-
ant role in transcriptional control [26]. While only a
small percentage of DMRs overlapped with annotated
exons (3.0 and 2.9 %), DMRs were abundant within in-
trons (48.6 and 43.1 %).
We also asked whether methylated promoter CpG
islands (CGIs), associated with repression of gene tran-
scription [27], are a feature of intestinal fibrosis (Fig. 1d).
The vast majority of differential DNA methylation was
found outside CGIs. For hypermethylated and hypo-
methylated DMRs, respectively, only 5.9 and 1.9 % were
in CGIs, 9.7 and 6.4 % in shores (2000-bp flanking CpG
islands), and 4.0 and 4.1 % in shelves (2000-bp flanking
shore regions). Of all the DMRs, the open sea regions
(loci greater than 4 kb from CpG islands) contained
most of the differential non-CpG island methylation
(86.3 and 87.7 %). Published data indicate that
alterations in DNA methylation outside CGIs in shelves/
shores can play a role in gene transcription and may be
cell-type specific [28].
Genome-wide transcriptome analysis of fibrotic and
normal intestinal fibroblasts
RNA-seq analysis identified the fibrosis-associated
changes in the HIF transcriptome associated with changes
in DNA methylation. Using established criteria for analyz-
ing RNA-seq data from normal and fibrotic RNA, we
found 72 genes that were differentially expressed (Benja-
min-Hochberg adjusted p value <0.05, FDR < 5 %, Fig. 2a
and Additional file 2). The consistency of gene expression
within each group is evident from the hierarchical cluster-
ing dendrogram. Of the 72 differentially expressed genes,
31 were downregulated and 41 upregulated. Only three
genes, toll-like receptor 4 (TLR4) [29], interleukin 33,
(IL-33) [30], and insulin-like growth factor 1 (IGF-1)
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Fig. 2 Differential gene expression profiles of HIF isolated from normal colons and Crohn’s Disease (CD) fibrotic colons. a Heatmap and hierarchical
clustering dendrogram of transcript abundance from RNA-seq performed on HIF RNA from three normal colons and three CD fibrotic colons depicting
differentially expressed genes with reduced expression in CD fibrotic colon compared to normal colon. Red represents up-regulation of the gene’s
expression, and blue down-regulation. b Heatmap depicting differentially expressed genes with increased expression in CD fibrotic colon compared to
normal colon. c Validation by RT-PCR of the fold change in PTGDS, PTGIS, and WNT2B mRNA levels in CD fibrotic versus control fibroblasts is shown
(n = 7; PTGDS p = 0.0074, PTGIS p = 0.021, and WNT2B p = 0.015)
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[31], have been previously reported or hypothesized to
have functions in intestinal inflammation, IBD, or other
fibrotic diseases [32, 33].
WNT2B, PTGIS, and PTGDS are subject to differential
expression and differential DNA methylation
We next examined which of the sharp yes/no DMRs in
promoter regions that overlapped with genes were differen-
tially expressed (Table 1). Promoter hypermethylation of
two protein-coding genes, wingless-type mouse mammary
tumor virus integration site family, member 2B (WNT2B)
[34] and prostacyclin synthase (PTGIS) [35], were inversely
correlated with alterations in their mRNA levels (Table 1).
Validation by RT-PCR showed that the changes in PTGIS
mRNA and WNT2B mRNA were decreased in fibrotic
compared with normal HIF (Fig. 2b), consistent with the
observed hypermethylation of each gene. In contrast, the
mRNA level of prostaglandin D2 synthase (PTGDS), an-
other member of the eicosanoid (prostaglandin) family [36],
was increased in fibrotic HIF (Fig. 2b). Bisulfite sequencing
was performed on the WNT2B, PTGIS, and PTGDS genes
(Figs. 3a, b and Additional file 3) to validate the DMRs
at base-pair resolution. The DMRs in the WNT2B and
PTGIS promoters were confirmed to be hypermethy-
lated (Fig. 3a, b). Bisulfite sequencing confirmed that
PTGDS was hypomethylated in a 550-bp region spanning
its promoter and coding sequence (Additional file 3).
These findings corroborate the corresponding changes in
expression and DNA methylation levels for all three genes
(Additional file 3, Figs. 2b and 3a, b).
Novel functional gene networks in Crohn’s disease-
associated fibrosis
As a first step in determining how differential DNA
methylation contributes to intestinal fibrosis pathogen-
esis, we used the GeneMANIA algorithm to predict
network-based functional associations between genes
differentially methylated and differentially expressed in
fibrotic HIF (list of input genes in Additional file 4). The
attributed functions fall into two main groups. The first
is extracellular matrix structure and organization, which
is highly relevant to fibrosis of the intestine and other fi-
brotic disorders [37, 38]. The second is guanine nucleo-
tide exchange factor signaling, including the small GTP
proteins RHO and RAC [39], previously described in
gastrointestinal ulcer healing and in other fibrotic dis-
eases but not in intestinal fibrosis [40, 41].
Sub-networks that include the three differentially
methylated and expressed genes WNT2B, PTGIS, and
PTGDS (Fig. 4) and the genes that interact with them
were identified (Additional files 5, 6, and 7). PTGDS and
PTGIS were associated with fibulin 1 (FBLN1) and IGF-1,
both linked with extracellular matrix structure and fibrosis
[31, 42]. PTGIS is also linked with other genes in-
volved in the organization and structure of the extra-
cellular matrix, for example, ADAM metalloprotease
with thrombospondin motifs 5 (ADAMTS5) and the
alpha 2 chain of type I collagen (COL1A2) [42–44].
There are also other interactions not previously de-
scribed in any fibrotic disease; for example, both
PTGDS and WNT2B are linked with vasohibin 2
Table 1 Genes differentially DNA methylated and expressed in fibrotic HIF
Gene symbol Hyper/hypo Location of DMR Fold change (B vs. A) Adjusted p value
WNT2B 01 Promoter + 5′ UTR + exon + intron 0.19 0
PTGIS 01 Promoter + intron 0.18 0
PTGDSa 10 Promoter + exon 6.44 0.01
COL24A1 01 Promoter + 5′ flank 5.94 0.01
OBSCN 01 Promoter + exon + intron 3.47 0.04
RAB38 01 Promoter + 5′ UTR + exon + 5′ flank 5.73 0
ARL4C 01 Intergenic + promoter + 5′ flank 3.43 0.04
CLIC6 01 Intergenic + promoter + 5′ flank 3.64 0.02
FBLN1 01 Intergenic + promoter + 5′ Flank 0.22 0
KALRN 01 Promoter + 5′ UTR + exon + intron + 5′ flank 3.64 0.03
DCDC2 01 Intergenic + promoter + 5′ flank 25.14 0.01
KCNH2 01 Promoter + exon + intron 0.13 0
IFI27 10 Promoter + 5′ UTR + exon + intron 4.06 0.04
AOC3 10 Promoter + 5′ UTR + exon + intron 0.04 1.16E−15
ADAMTS5 10 Promoter + intron 5.11 0
The genes that were found to be both differentially DNA methylated in their promoter regions and inversely correlated with gene expression are shown. Hyper/
hypo column denotes whether genes are yes/no hyper- (01) or hypo- (10) methylated in fibrotic HIF. Italicized 01 and 10 represent genes that were quantitatively
differentially DNA methylated and not analyzed further in this study. The location of the DMR, the fold change in mRNA expression detected by RNA-seq, and the
adjusted p value are shown
aPTGDS fold change and p values are from RT-PCR validation
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(VASH2) [45] and chromosome 7 open reading frame
69 (C7orf69).
Discussion
The objective of our studies was to obtain novel insights
into the molecular mechanisms that underlie intestinal
fibrogenesis. Through definition and integration of the
DNA methylome and transcriptome, we have revealed
functional candidate gene networks for three protein-
coding genes: WNT2B, PTGIS, and PTGDS, which have
not previously been described in CD or other fibrotic
diseases. By employing the next generation sequencing-
based approach, MiGS [24] and RNA-seq, we were able
to achieve genome-wide coverage and improved accur-
acy over previous studies that have used microarrays to
profile changes in DNA methylation and gene expres-
sion in inflammatory bowel disease and other fibrotic
disorders.
Our experiments were performed in HIF purified from
fibrotic or normal colon tissue to minimize the con-
founding effects of cell type heterogeneity of whole
blood or tissue that have been widely used in previous
Fig. 3 Bisulfite sequencing validation of differentially methylated WNT2B and PTGIS in fibrotic versus control HIF. a On the left, UCSC genome
browser capture showing the MiGS read depth for three CD fibrotic (CD) and three control colon (NL) samples that shows the WNT2B promoter
DMR and adjacent flanking regions. The range for the methylation counts (y-axis) for all samples in the UCSC genome browser was set at 0 to
150. The solid black box underneath the browser screen capture shows the location of the yes/no DMR region called from the MiGS data. On the
right, targeted bisulfite sequencing validation of a region overlapping the DMR as indicated by the rectangle over the genome browser tracks.
Dark circles indicate methylated and open circles unmethylated cytosines. Each row consists of a single sequenced clone. b MiGS data and
targeted bisulfite sequencing illustrated as in (a) for PTGIS. The y-axis scale for all samples in the browser capture was set at 0 to 75 reads
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epigenetic studies [28]. The large number, size, and
genome-wide distribution of DMRs in fibrotic HIF sug-
gest that this epigenetic modification has an important
role in intestinal fibrosis. We observed sharp yes/no dif-
ferences in DNA methylation throughout the genic and
intergenic regions of the fibrotic HIF genome. Only a
comparatively low percentage of DMRs occurred in pro-
moters of genes and in CpG islands. The vast majority
of DMRs were located within introns and intergenic re-
gions. Intergenic sequences contain enhancers and insu-
lators that are associated with regulation of gene
expression during differentiation and organogenesis
[7, 8]. Other distinct functions for DNA methylation
have been proposed within introns and CpG island
shores [28, 46, 47]. For example, DNA methylation in
introns can modulate alternative exon splicing [46, 47]
and in shores, differential DNA methylation is tissue-
specific and may regulate transcription from alternative
start sites [28].
The precise mechanism by which DNA methylation
regulates gene transcription remains poorly defined.
Methylated CpGs can prevent the binding of some
Fig. 4 Interaction network for genes differentially expressed and differentially DNA methylated in fibrotic HIF. The blue circles represent the genes
entered into the Cytoscape plugin for GeneMANIA. While the network was built for all differentially expressed genes, only the interactions from
the subset that show both differential expression and DMRs are shown here. The gray circles are additional genes closely associated with the
input genes. The size of the circle (node) is the number of neighbors each gene connects to. The edges are indicated by associations found
through previously published co-expression, co-localization, and genetic and physical interactions. The genes/nodes with edges connected to
PTGDS are colored green, the edges that connect to PTGIS are colored violet, and those to WNT2B are colored red
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transcription factors [7], and other evidence indicates
that methylation of DNA can alter nucleosome occu-
pancy and alternative polyadenylation of mRNA during
transcription [48–50]. Whether de novo DNA methyla-
tion directly represses genes or whether gene silencing
precedes or follows methylation is still debated, but the
available evidence indicates that this will be dependent
in large part on the genomic location of the methylated
DNA sequence [7, 8]. This is a rapidly advancing area
with new compelling evidence for causal associations be-
tween DNA methylation changes and phenotype [51, 52].
Our detection of DMRs provides a resource of candidate
loci for future work to understand the role of DNA methy-
lation in different genomic locations at different stages of
pro-fibrotic gene expression.
We identified three genes: WNT2B, PTGIS, and
PTGDS in which differential methylation of the DNA
in each promoter region was inversely correlated with
gene expression in fibrotic HIF. Complex roles for the
WNT signaling pathway in the fibrosis of a number of
organs including the lung and kidney and in control-
ling tissue homeostasis, cell proliferation, migration,
differentiation, apoptosis, and organogenesis have
been reported [53, 54]; however, this family of genes
has not previously been associated with intestinal fi-
brosis. The decreased expression of hypermethylated
WNT2B is a novel finding both in the context of fibro-
sis and CD. Interestingly, increased expression of
WNT2B has been detected in the intestinal mucosa of
UC patients [55], suggesting that WNT2B may per-
form distinct functions in CD and UC.
In the case of the prostaglandin family, central func-
tions are well-established in homeostasis, inflammation,
and other fibrosis disorders [56]. Profibrogenic func-
tions for prostaglandin F2α and anti-fibrotic effects of
prostaglandin E2 have been documented in lung fibrosis
[57, 58]. In addition, the product of PTGIS catalysis,
PGI2, has been shown to be anti-fibrotic in the lung
[56] and also in a prostacyclin receptor null mouse
model of cardiac fibrosis [59]. We found that PTGIS
was hypermethylated and repressed in fibrotic HIF.
Hypermethylation of the PTGIS promoter is a feature
of colorectal cancer, but decreased expression of PTGIS
has not previously been linked with IBD [60]. A further
finding of our studies was that the lipocalin-type
PTGDS gene was hypomethylated and its mRNA levels
increased in fibrotic HIF. Our observations are sup-
ported by studies showing (i) increased levels of lipoca-
lin type PTGDS in colitis, (ii) increased expression in
UC patients in parallel with disease activity, and (iii)
decreased DSS-induced colitis in L-PTGDS knockout
mice [61]. Conflicting data in other studies indicate
that in the kidney, PGD2, the product of PGDS catalytic
activity, promotes the development of tubulointerstitial
fibrosis [62], whereas a protective function of PGD2 has
been reported in TNBS colitis [63]. These observations
may reflect tissue-specific differences or methodo-
logical discrepancies between the aforementioned
studies.
Based on previous studies including a recent study of
fibrotic liver disease, the average age difference of
20 years between our fibrotic Crohn’s disease and nor-
mal patient groups is highly unlikely to be a confound-
ing factor in the differential DNA methylation we
identified [23]. Comparison of the DNA methylomes of
dermal fibroblasts from individuals with a much greater
disparity in age (<23 years old vs. >60 years old)
showed a change in DNA methylation levels of >15 %
at only 75 CpG sites, none of which were highly signifi-
cant (p < 0.001) [64]. More importantly, none of these
sites were differentially methylated in fibrotic HIF.
Studies in tissues such as the heart, and in diseases
such as cancer, indicate that the same epigenetic path-
ways that are beneficial in organ development are per-
turbed in the fully developed or diseased tissue. The
concept of antagonistic pleiotropy [65] suggests that key
pathways are advantageous at early stages of develop-
ment, e.g., in myofibroblast differentiation and wound
healing, but in later life, these same pathways become
detrimental as they promote myofibroblast activation
and progressive fibrosis [65, 66]. Thus, the available evi-
dence indicates that alterations in DNA methylation
during development could serve as key determinants of
the pro-fibrotic phenotype. Together with genetic and
environmental factors, DNA methylation could be a
major contributor to the progression of injury in CD
and to the establishment of intestinal fibrosis. An im-
portant aim of future studies will be to determine
changes in DNA methylation in patients with different
stages of fibrostenotic CD. This could help stratify dis-
tinct subtypes of CD and identify those patients most
likely to develop intestinal fibrosis
Conclusions
Our detailed map of the methylome integrated with the
transcriptome has revealed fibrosis-associated regulation
of WNT2B, PTGIS, and PTGDS. The networks for these
genes reveal interactions with other factors important in
development and extracellular matrix synthesis. This
suggests that key sites of differential DNA methylation
can lead to the molecular aberrations that underlie IBD-
associated fibrosis and provide potential targets for fu-
ture development of prognostic strategies and specific
anti-fibrotic therapies. Our data also provide a basis for
defining the contribution of genome-wide changes in
DNA methylation to the pathogenesis of fibrotic
disorders.
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Methods
Colon tissue and cell culture
Colon resection specimens were obtained from patients
with CD-associated fibrosis and control colon speci-
mens were obtained from histologically normal tissue
from patients with diverticulitis (Additional file 8)
under the approval of the Cleveland Clinic institutional
review board (IRB 06-050). The approved protocol in-
cluded a waiver of informed consent for redundant tis-
sues obtained through the Cleveland Clinic Human
Tissue Procurement Facility in accordance with Cleve-
land Clinic IRB policy. Tissue specimens were de-
identified and made available following authorization
by a Cleveland Clinic surgical pathologist. Human in-
testinal fibroblasts (HIF) were cultured from colon
specimens and their purity confirmed as previously re-
ported by established methods [67].
DNA methylome profiling
Genome-wide DNA methylation was mapped using
methyl-CpG binding domain-isolated genome sequencing
(MiGS) [24], with the following differences. Genomic
DNA (DNEasy kit, Qiagen) was extracted from normal
and fibrotic cultured HIF. DNA (10 μg) was sheared on a
Covaris S220 to an average size of 120 bp. Methylated
DNA fragments were purified on PrepEase DNA columns
(USB) and captured with the methyl-CpG binding protein
MBD2 (MethylMiner Methylated DNA Enrichment kit
#ME10025, Invitrogen). A sequencing library for each
immunoprecipitated DNA sample was prepared using
Ilumina’s ChIP-seq DNA Sample Prep Kit. The quality of
the DNA was assessed on an Agilent Bioanalyser. Sequen-
cing libraries of methylated DNA fragments were analyzed
and next generation sequencing performed on an Ilumina
HiSeq 2000. Read lengths of 50 bp were sequenced at an
average depth of 161,226,405 reads (minimum:
130,528,176 reads, maximum: 190,943,105 reads). Reads
were aligned to assembly hg19 of the human genome
(Genome Reference Consortium Human Build 37) using
the bowtie2 short read alignment software (options: -N 1
-L 20 –phred33) [68].
Bioinformatic analysis of differential DNA methylation
Differential DNA methylation was detected using the in-
tegrated signal deconvolution, pattern recognition, and
differential testing (iDPT) framework [69] (https://idpt.
github.io/dptscan/). Using this framework, reads were
extended to the average fragment length. Average cover-
age (e.g., averages of the per-base coverage rounded to
integers) was computed within 50-bp non-overlapping
windows tiling the entire genome. Initial filtering re-
moved all windows where no sample had a read count
above a false discovery threshold established by a Poison
distribution that assumed an even coverage of reads
across the genome. Signal deconvolution was performed
using a Bayesian mixture of three Poisons model, produ-
cing a probability of methylation for each window in
each sample. Pattern recognition used these probabilities
and a scan statistic to produce regions of consistent
methylation status, allowing for small gaps.
Finally, differential testing was performed using a
linear mixed-effects model and an output table that
contained fold changes, and multiple testing-adjusted
p values for each DMR was produced. The output dif-
ferentiated between sites showing a sharp yes/no
methylation difference (defined as all samples in one
group are predicted by the model to have no methyla-
tion, and all samples in the other group are predicted
to be methylated) versus sites that show a quantitative
difference in reads (the model predicts all samples
across all groups to be methylated, but the read counts
show a statistically significant difference). Only the
sharp sites were used for subsequent analysis because
they are more likely to represent differential DNA
methylation rather than other phenomena that can
change read counts, such as copy number variation.
The R package goldmine was used to analyze the gen-
omic context of the detected regions with respect to
known genes and features (http://jeffbhasin.github.io/
goldmine). The goldmine functions, getCpgFeatures, get-
Features, and getGenes were used to obtain CpG islands,
ENCODE supertracks, and RefSeq gene models from the
database of the UCSC Genome Browser [70, 71]. This
data was used by the goldmine function to provide de-
tailed annotation of how these datasets relate to the
regions.
RNA sequencing
For RNA sequencing (RNA-seq), RNA was extracted
from control and fibrotic HIF using the RNEasy mini kit
(Qiagen). A gene sequencing library for each sample
(1 μg RNA) was prepared using the TruSeq™ RNA Sam-
ple Prep Kit v2. Next generation sequencing was per-
formed on an Illumina HiSeq 2500. After quality
assessment, reads were aligned to hg19 using GSNAP
[72]. Read lengths of 100 bp were sequenced at an aver-
age depth of 53,390,000 reads (minimum 39,470,000
reads, maximum 62,550,000 reads). Only reads that
aligned to a single locus in the hg19 genome assembly
were retained for further analysis. Read counts for
RefSeq genes were computed using HTSeq-count pro-
gram [73]. Differential expression analysis was per-
formed on this count table using the negative binomial
test provided by the DESeq package [74] in the R statis-
tical computing environment (http://www.R-project.org/).
Transcripts with p values less than 0.05 after adjustment
by the Benjamini-Hochberg procedure were considered
statistically significant.
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Bisulfite sequencing
For validation of DMRs detected by the genome-wide
DNA methylome analysis, genomic DNA (330 ng) was
prepared using the DNEAsy kit (Qiagen). Bisulfite con-
version of the DNA was performed with the EZ DNA
Methylation-Lightning Kit #D5030 (Zymo). Bisulfite-
converted DNA (1 μl) was amplified by PCR with iTaq
DNA polymerase (BioRad), and primers were designed
using the MethPrimer website (see Additional file 9).
DNA was cloned (Topo TA cloning kit, K4575-01, Invi-
trogen), and the cloned DNA (prepared using PureLink
Miniprep kit, Invitrogen) was digested with EcoR1 to
verify cloning of the inserted DNA. DNA from at least
ten different clones was then sequenced at the Genomics
Core of Cleveland Clinic’s Lerner Research Institute.
DNA methylation of individual CpG sites was analyzed
using Quma software (http://quma.cdb.riken.jp/).
Reverse transcriptase PCR (RT-PCR)
For validation of changes in mRNA levels of differen-
tially DNA methylated genes, total RNA was extracted
from fibrotic and normal HIF and reverse transcribed,
and complementary DNA (cDNA) was amplified by RT-
PCR. Five microliters of cDNA was amplified in the
presence of 0.125 μmol/L each of the 5′ and 3′ primers
(Biosynthesis, Lewisville, TX) and 1 U of Taq DNA poly-
merase (Roche, Mannheim, Germany). PCR was per-
formed in a DNA thermal cycler using pre-optimized
temperatures and times, and the primers (listed in
Additional file 9) were used to quantify mRNA levels.
Fifteen microliters of the PCR product were subjected to
electrophoresis on 1.5 % agarose gel and stained with
0.5 μg/ml ethidium bromide, using 100 bp DNA ladder
as a marker.
GeneMANIA network analysis
The GeneMANIA algorithm (version 3.2.1, http://
www.genemania.org) employs functional interaction data
to create a network containing putative functional links
between genes. We used the GeneMANIA Cytoscape
plugin [75] to generate a network for the genes identi-
fied in this study based on protein-protein interactions,
genetic interactions, and co-expression profile databases.
Data on shared protein domains and co-localization
were eliminated from the analysis, to minimize the num-
ber of false positives. A sub-network was extracted by
restricting the network to only nodes that interact with
defined genes of interest and was plotted using Gephi
(https://gephi.github.io/).
Availability of supporting data
The DNA methylation and RNA-seq data sets (raw and
normalized) supporting the results of this article are avail-




Additional file 1: Table S1. Differentially methylated regions (DMRs)
between normal and fibrotic HIF. Each row represents one DMR. For
each DMR, a unique ID, coordinates in the form of chr, start, end (hg19),
and the DMR width are provided. Each DMR is categorized by a pattern
code: “01” represents hypermethylation in fibrotic samples, and “10”
represents hypomethylation in fibrotic samples. The “ratio” column
represents the magnitude of the difference in sequencing signal as a
log2 fold change, “p.value” is the unadjusted p value, and “q.value” is the
Benjamini-Hochberg adjusted p value. “Genomic_context” specifies if the
DMR falls within a portion of an annotated gene model. Multiple overlaps
are resolved using the priority: promoter > exon > intron > 3′ end >
intergenic. Overlap with CpG shores, islands, and shelves is provided,
along with the distance to the nearest gene and the names of the
nearest genes. (XLS 461 kb)
Additional file 2: Table S2. RNA-seq analysis of differentially expressed
genes in control and fibrotic HIF. Total mRNAs from three different
normal (2, 3, 4) and fibrotic fibroblasts (6, 7, 8) were subjected to RNA-seq
analysis. Normalized FPKM values were averaged and the log base
twofold change for fibrotic versus normal HIF calculated. FDR adjusted
p values are shown. Genes were considered significant if the adjusted
p value was <0.05 and the log fold change was at least 1.5-fold. The
differentially expressed genes are highlighted. (XLS 45 kb)
Additional file 3: Figure S1. Bisulfite sequencing validation of
differentially methylated PTGDS in fibrotic versus control HIF. UCSC
genome browser capture (left panel) of regions of differential DNA
methylation for PTGDS from MiGS are shown next to the corresponding
region of the gene validated by bisulfite sequencing (right panel). Three
CD fibrotic (top panel) and three control (NL, lower panel) samples are
shown. Dark circles indicate methylated and open circles unmethylated
cytosines. Each row consists of a single sequenced clone. The range for
the methylation counts (y-axis) in the UCSC genome browser was set at
1 to 128. (TIFF 1517 kb)
Additional file 4: Table S3. List of input genes for GeneMANIA. The list
of genes used to construct an interaction network in GeneMANIA in
order to obtain functional enrichment is provided. A subset of the
identified interactions are shown in Fig. 4. (XLSX 9 kb)
Additional file 5: Table S4. Network gene associations for WNT2B. List
of genes in RNA-seq data set (bold italics) and in GeneMANIA database
(italics) that interact with WNT2B are shown. (XLSX 45 kb)
Additional file 6:Table S5. Network gene associations for PTGIS. List of
genes in RNA-seq data set (bold italics) and in GeneMANIA database
(italics) that interact with PTGIS are shown. (XLSX 45 kb)
Additional file 7:Table S6. Network gene associations for PTGDS. List of
genes in RNA-seq data set (bold italics) and in GeneMANIA database
(italics) that interact with PTGDS are shown. (XLSX 41 kb)
Additional file 8: Table S7. Patient characteristics. The characteristics of
the patients with Crohn’s disease and controls from whom colon
specimens were obtained for the DNA methylome and RNA Seq analyses
are shown. (XLSX 9 kb)
Additional file 9: Table S8. Primers for gene expression and bisulfite
sequencing. The bisulfite sequencing primers for specific chromosomal
locations and the qRT-PCR primer sequences and accession numbers, for
WNT2B, PTGIS, and PTGDS are shown. (XLSX 11 kb)
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